SanBio Co Ltd (JP:4592)
:4592
Want to see JP:4592 full AI Analyst Report?
Top Page
SanBio Co
(4592)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥2,049.00
▼(-8.12% Downside)
Action:ReiteratedDate:03/21/26
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and persistent cash burn) and bearish technical conditions (price below key moving averages and negative MACD). Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Proprietary cell-based platform
Owning a proprietary cell-based platform is a durable strategic asset: it supports multiple programs, creates barriers to entry, and enables partnering or licensing deals. For a clinical-stage biotech this long-term platform value can generate milestone and royalty revenue before commercial sales.
Negative Factors
Zero revenue and persistent losses
Having no commercial revenue places the company squarely in development-stage risk: ongoing trial costs without product sales mean value depends entirely on trial success, partnerships, or licensing. Persistent large losses erode investor capital and delay any path to self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell-based platform
Owning a proprietary cell-based platform is a durable strategic asset: it supports multiple programs, creates barriers to entry, and enables partnering or licensing deals. For a clinical-stage biotech this long-term platform value can generate milestone and royalty revenue before commercial sales.
Read all positive factors
SanBio Co (4592) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥153.74B
Dividend YieldN/A
Average Volume (3M)2.08M
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-25.72%
CountryJP
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,041,885
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,866.67Price Target Upside-16.29% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SanBio Co Business Overview & Revenue Model
Company Description
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan....
How the Company Makes Money
null...
SanBio Co Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jan 2026 | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.26M | -8.05M | -9.37M | -14.50M | -24.61M | -132.47M |
| EBITDA | -3.82B | -3.79B | -3.51B | -4.53B | -7.87B | -6.49B |
| Net Income | -3.57B | -3.84B | -2.88B | -2.64B | -5.56B | -4.68B |
Balance Sheet | ||||||
| Total Assets | 3.22B | 15.62B | 3.45B | 5.05B | 7.05B | 5.51B |
| Cash, Cash Equivalents and Short-Term Investments | 2.74B | 15.08B | 2.92B | 4.45B | 6.73B | 4.56B |
| Total Debt | 1.36B | 1.24B | 397.00M | 665.00M | 933.00M | 2.52B |
| Total Liabilities | 1.93B | 2.02B | 1.68B | 2.25B | 2.62B | 3.48B |
| Stockholders Equity | 1.29B | 13.60B | 1.76B | 2.79B | 4.43B | 2.04B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -3.84B | -3.62B | -4.79B | -7.46B | -6.61B |
| Operating Cash Flow | 0.00 | -3.81B | -3.62B | -4.78B | -7.45B | -6.57B |
| Investing Cash Flow | 0.00 | -231.04M | -4.27M | -19.03M | -10.10M | -66.26M |
| Financing Cash Flow | 0.00 | 16.01B | 2.10B | 2.38B | 9.46B | -1.47B |
SanBio Co Technical Analysis
Positive
2230.00
Price Trends
2023.76
Positive
1925.00
Positive
2248.68
Negative
Market Momentum
11.59
Negative
56.45
Neutral
65.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4592, the sentiment is Positive. The current price of 2230 is above the 20-day moving average (MA) of 1925.00, above the 50-day MA of 2023.76, and below the 200-day MA of 2248.68, indicating a neutral trend. The MACD of 11.59 indicates Negative momentum. The RSI at 56.45 is Neutral, neither overbought nor oversold. The STOCH value of 65.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4592.
SanBio Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.45B | 120.78 | ― | ― | -7.33% | -167.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥22.46B | -34.16 | ― | ― | -11.11% | -187.80% | |
50 Neutral | ¥44.96B | -13.30 | ― | ― | -81.43% | 48.15% | |
49 Neutral | ¥10.53B | -8.14 | ― | ― | -56.71% | -23.09% | |
45 Neutral | ¥18.74B | -11.30 | ― | ― | ― | 13.18% | |
43 Neutral | ¥153.74B | -35.18 | -253.07% | ― | ― | -25.72% |
* Healthcare Sector Average
JP:4592
SanBio Co
1,970.00
-329.00
-14.31%
JP:4593
Healios KK
333.00
16.00
5.05%
JP:4599
StemRIM Inc.
299.00
-13.00
-4.17%
JP:4978
ReproCELL Inc.
173.00
33.00
23.57%
JP:7774
Japan Tissue Engineering Co., Ltd.
553.00
-77.00
-12.22%
JP:7776
CellSeed Inc.
270.00
-259.00
-48.96%
SanBio Co Corporate Events
SanBio Outlines FY2026 Results and Global Regenerative Medicine Ambitions
Mar 25, 2026
SanBio has released its financial results for the fiscal year ending January 31, 2026, along with forecasts for the current fiscal year, underscoring its ongoing commitment to regenerative medicine. The company also highlighted its strategic goal ...
SanBio to Restructure Capital to Eliminate Deficit and Boost Financial Flexibility
Mar 17, 2026
SanBio plans to reduce its stated capital by 1.7 billion yen and capital reserves by a similar amount, reallocating these funds to other capital surplus to eliminate a retained earnings deficit of 3.4 billion yen recorded at the end of the fiscal ...
SanBio Books Foreign Exchange Losses and Financing Costs in FY2026 Results
Mar 17, 2026
SanBio Co., Ltd. reported several non-operating expenses for the fiscal year ending January 31, 2026, including ¥29 million in bond interest tied to convertible bonds with stock acquisition rights and a ¥45 million charge in financing ex...
SanBio Deepens Losses but Fortifies Balance Sheet as It Awaits AKUUGO Revenue
Mar 17, 2026
SanBio reported another year of losses for the fiscal year ended January 31, 2026, posting an operating loss of ¥3.79 billion and net loss of ¥3.84 billion, while operating revenue remained at zero. Despite the continued red ink, the com...
SanBio Finalizes Employee Stock Option Terms for 75,000 Shares
Jan 27, 2026
SanBio has finalized the terms for a new stock option program, approving the issuance of 75,000 share acquisition rights tied to an equal number of common shares at an exercise price of 1,898 yen per share. All of the options will be granted to th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.